First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers

2007283 citationsJournal Articlebronze Open Access

Authors

James C. Gilbert · Mahindra and Mahindra Limited (India)

Tia DeFeo-Fraulini · Mahindra and Mahindra Limited (India)

Renta Hutabarat · Mahindra and Mahindra Limited (India)

Christopher Horvath · Mahindra and Mahindra Limited (India)

Patricia G. Merlino · Mahindra and Mahindra Limited (India)

H. Nicholas Marsh · Mahindra and Mahindra Limited (India)

Judith M. Healy

Abstract

This is the first-in-human evaluation of a novel aptamer antagonist of vWF. ARC1779 produced dose- and concentration-dependent inhibition of vWF activity and platelet function with duration of effect suitable for the intended clinical use in acute coronary syndromes.

Topics & Keywords

Platelet Disorders and Treatments Blood groups and transfusion Complement system in diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Circulation

Volume 116, Issue 23, pp. 2678-2686

DOI: 10.1161/circulationaha.107.724864

Field-Weighted Citation Impact: 12.24